LEPU BIOPHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.04 HKD | +7.23% |
|
+16.94% | +19.71% |
| Apr. 12 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
| Mar. 27 | Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
LePU Biopharma Co Ltd is a China-based biopharmaceutical company focused on tumor treatment. The Company mainly develops product lines of tumor candidate drugs, including antibody drug conjugate (ADC), oncolytic virus drug products and immunotherapy at clinical and pre-clinical stages. The Companyâs major pipeline assets consist of MRG003, MRG002, HX008 and LP002, and three key clinical-stage drug candidates. The Company's products are sold at home and abroad.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
4.665
CNY
Average target price
3.403
CNY
Spread / Average Target
-27.06%
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +19.71% | 1.07B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 2157 Stock
- News Lepu Biopharma Co., Ltd.
- US FDA Grants Fast Track Designation to Lepu Biopharma's Anti-Cancer Drug
